tetrabenazine

Tetrabenazine (Ro 1-9569) is a former antipsychotic drug used to treat various movement disorders. It inhibits neurotransmitter uptake into adrenergic storage vesicles and serves as a high-affinity label for the vesicle transport system.

Tetrabenazine Racemate (Rubigen) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2). Tetrabenazine Racemate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affinity label for the vesicle transport system.

(+)-Tetrabenazine ((3R,11bR)-Tetrabenazine) is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Tetrabenazine Metabolite ((-)-β-HTBZ), a vesicles monoamine transporter 2 (VMAT2) inhibitor, is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite has a high affinity for VMAT2 with a Ki of 13.4 nM. Tetrabenazine Metabolite is often used to study chorea associated with Huntington's disease and other hyperactivity disorders.

Tetrabenazine D6 is the deuterium-labeled Tetrabenazine. Tetrabenazine is a VMAT-inhibitor used for the treatment of hyperkinetic movement disorder.

Tetrabenazine methanesulfonate is a medicine formerly utilized as an antipsychotic and therapy for various movement disorders. Tetrabenazine methanesulfonate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affin

(3R,11bR)-Tetrabenazine-d6 is a deuterated compound of (3R,11bR)-Tetrabenazine. (3R,11bR)-Tetrabenazine has a CAS number of 1026016-83-0. (+)-Tetrabenazine is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.

Trans (2,3)-Dihydrotetrabenazine is a Tetrabenazine metabolite, shows inhibition activity on vesicular monoamine transporter (VMAT2).

Deutetrabenazine metabolite M4 is believed to be related to its effect as a reversible depletion of monoamines from nerve terminals. The major circulating metabolites of Deutetrabenazine, are reversible inhibitors of VMAT2, resulting in decreased uptake

JJC8-089, a dopamine transporter (DAT) inhibitor, might enhance motivation-related dysfunctions by increasing effortful behavior in goal-oriented activities. This compound significantly counteracted the low-effort effects induced in rats by the VMAT-2 inhibitor Tetrabenazine, and elevated the selection of high-effort fixed ratio 5 lever presses associated with food intake.